Xiang-Peng Kong, Jacques Le Pendu, Selvakumar Subbian, Dennis K. Lanning, Ana M. Lopes, Natalie Ruvoën-Clouet, Katherine L. Knight, Joana Abrantes, Javier González-Gallego, Xuwen Peng, Lbachir BenMohamed, Ana Acacia S. Pinheiro, Michael Vaine, Lorenzo Giacani, Rose G. Mage, Neil D. Christensen, Wessel van der Loo, Shuying Liu, Pedro J. Esteves, María J. Tuñón, Fabiana Neves, Masmudur M. Rahman, Yuxing Chen, Hanna Mari Baldauf, Ana Lemos de Matos, Ruimin Pan, Jia Liu, Laura E. Via, Patrícia de Sousa-Pereira, Jiafen Hu, Shixia Wang, Oliver T. Keppler, Grant McFadden, Shan Lu, Sheila A. Lukehart, Gilla Kaplan, Yukari C. Manabe, CIBIO, InBIO, Research Network in Biodiversity and Evolutionary Biology, Universidade do Porto, Departamento de Biologia, Faculdade de Ciências da Universidade do Porto, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde - CESPU [Gandra, Portugal], Max von Pettenkofer Institute and Gene Center, Ludwig-Maximilians-Universität München (LMU), Laboratory of Cellular and Molecular Immunology, University of California [Irvine] (UCI), University of California-University of California, Department of Molecular Biology and Biochemistry, Institute for Immunology, Department of Medicine, University of Massachusetts Medical School [Worcester] (UMASS), University of Massachusetts System (UMASS)-University of Massachusetts System (UMASS), Departments of Pathology, Microbiology and Immunology, and Comparative Medicine, Pennsylvania State University (Penn State), Penn State System-Penn State System, Institute of Biomedicine (IBIOMED) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Léon, Departments of Medicine and Global Health, University of Washington [Seattle], Bill & Melinda Gates Foundation [Seattle], Department of Microbiology and Immunology, Loyola University [Chicago], Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, NYU System (NYU)-NYU System (NYU), Host-Pathogen Interactions in the Regulation of Immune Responses (CRCINA-ÉQUIPE 5), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), The Biodesign Institute, Center for Immunotherapy, Vaccines, and Virotherapy, Arizona State University [Tempe] (ASU), University of Arkansas for Medical Sciences (UAMS), Department of Anatomy and Unit for Multidisciplinary Research in Biomedicine (UMIB), Universidade do Porto-Institute of Biomedical Sciences Abel Salazar - ICBAS [Porto, Portugal], Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine [Baltimore], Public Health Research Institute [Newark] (PHRI), Tubercolosis Research Section, Laboratory of Clinical Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases - NIH (National Institutes of Health), Institute of Infectious Disease and Molecular Medicine, Department of Clinical Laboratory Sciences, University of Cape Town, Laboratory of Immune System Biology, Universidade do Porto = University of Porto, University of California [Irvine] (UC Irvine), University of California (UC)-University of California (UC), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Universidade do Porto = University of Porto-Institute of Biomedical Sciences Abel Salazar - ICBAS [Porto, Portugal], and Bernardo, Elizabeth
Studies using the European rabbit Oryctolagus cuniculus contributed to elucidating numerous fundamental aspects of antibody structure and diversification mechanisms and continue to be valuable for the development and testing of therapeutic humanized polyclonal and monoclonal antibodies. Additionally, during the last two decades, the use of the European rabbit as an animal model has been increasingly extended to many human diseases. This review documents the continuing wide utility of the rabbit as a reliable disease model for development of therapeutics and vaccines and studies of the cellular and molecular mechanisms underlying many human diseases. Examples include syphilis, tuberculosis, HIV-AIDS, acute hepatic failure and diseases caused by noroviruses, ocular herpes, and papillomaviruses. The use of rabbits for vaccine development studies, which began with Louis Pasteur’s rabies vaccine in 1881, continues today with targets that include the potentially blinding HSV-1 virus infection and HIV-AIDS. Additionally, two highly fatal viral diseases, rabbit hemorrhagic disease and myxomatosis, affect the European rabbit and provide unique models to understand co-evolution between a vertebrate host and viral pathogens., Infectious disease: A leap forward for disease models Rabbits offer a powerful complement to rodents as a model for studying human immunology, disease pathology, and responses to infectious disease. A review from Pedro Esteves at the University of Porto, Portugal, Rose Mage of the National Institute of Allergy and Infectious Disease, Bethesda, USA and colleagues highlights some of the areas of research where rabbits offer an edge over rats and mice. Rabbits have a particularly sophisticated adaptive immune system, which could provide useful insights into human biology and produce valuable research and clinical reagents. They are also excellent models for studying - infectious diseases such as syphilis and tuberculosis, which produce pathology that closely resembles that of human patients. Rabbit-specific infections such as myxomatosis are giving researchers insights into how pathogens and hosts can shape each other’s evolution.